Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Exenatide once weekly versus insulin glargine for Type 2 diabetes (DURATION - 3): 3-year results of an open-label randomised trial.